Back to search results

Clinical Trial of MK-7262 and Enlicitide for High Lipoprotein(a)

This study is testing two trial medicines, MK-7262 and enlicitide, to see if they can lower high levels of Lipoprotein(a) (Lp(a)) and LDL-C (bad cholesterol). Researchers want to know if these medicines work better than a placebo (an inactive pill) when taken alone or together, and if they are safe. You may be able to join if you are 18 or older, have Lp(a) levels of 150 nmol/L or higher, and are on a stable dose of statin medication. The study will measure changes in Lp(a) and LDL-C at 8 weeks, and track any side effects for about 20 weeks. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 750 participants. It will compare MK-7262 and enlicitide, alone and together, against placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your Lp(a) and LDL-C levels will be measured at 8 weeks. Safety will be monitored for up to approximately 20 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07614984

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Merck Sharp & Dohme LLC
~750 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:MK-7262EnlicitidePlacebo for MK-7262Placebo for enlicitide

At a glance

Recruiting sites
20 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8
Measured over Baseline and Week 8
+3 more outcomes measured

Conditions

Lipoprotein(a)

Explore related trials

ALipoprotein (a)

Where it's being run

20 sites across 13 states
Florida5
Alabama2
California2
Maryland2
Connecticut1
Michigan1
Montana1
New Mexico1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Merck Sharp & Dohme LLC

Who to contact

Toll Free Number
[email protected]
1-888-577-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has Lp(a) ≥ 150 nmol/L
Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study

Exclusion

Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH
Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization
Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)
Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection
Has a history of nephrotic syndrome
Has severe renal insufficiency
Has received certain therapies in the prohibited timeframe as specified in the protocol
Has active or chronic hepatobiliary or hepatic disease
Has poorly controlled Type 1 or Type 2 diabetes

What this trial measures

  • Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8Baseline and Week 8

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change from baseline in Lp(a).

  • Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8Baseline and Week 8

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C.

  • Number of Participants who Experience One or More Adverse Events (AEs)Up to approximately 20 Weeks

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

  • Number of Participants Who Discontinue Study Intervention Due to an AEUp to approximately 12 Weeks

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.